000301290 001__ 301290
000301290 005__ 20250518020613.0
000301290 0247_ $$2doi$$a10.1111/nan.70018
000301290 0247_ $$2pmid$$apmid:40356449
000301290 0247_ $$2ISSN$$a0305-1846
000301290 0247_ $$2ISSN$$a1365-2990
000301290 0247_ $$2altmetric$$aaltmetric:177077170
000301290 037__ $$aDKFZ-2025-00974
000301290 041__ $$aEnglish
000301290 082__ $$a610
000301290 1001_ $$aRuiz, Fernanda$$b0
000301290 245__ $$aTesting Meningiomas With Methylation Arrays: Insights and Recommendations From a Large Single-Centre Study.
000301290 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2025
000301290 3367_ $$2DRIVER$$aarticle
000301290 3367_ $$2DataCite$$aOutput Types/Journal article
000301290 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747216074_6675
000301290 3367_ $$2BibTeX$$aARTICLE
000301290 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301290 3367_ $$00$$2EndNote$$aJournal Article
000301290 520__ $$aMeningiomas are common primary CNS tumours, and their morphological diagnosis is usually straightforward. Their histological grading according to CNS WHO criteria alone provides limited information on recurrence risk. Risk stratification of meningiomas combining WHO grade, methylation class and copy number profile improves prediction of the risk of early recurrence. Because of the frequency of meningiomas in diagnostic practice, applying this prediction algorithm to all meningiomas is financially not viable in most healthcare systems.We analysed a retrospective dataset of over 1000 meningiomas from a single centre with methylation arrays to provide guidance on which meningiomas to prioritise for integrated molecular testing and to understand how WHO grades resolve into risk strata.Approximately 90% of CNS WHO Grade 1 meningiomas were allocated into the methylation class 'benign' and also into a low-risk group. Grade 2 meningiomas were allocated almost equally to either the low-risk (39%) or intermediate-risk groups (46%) but occasionally also to the high-risk group (15%). All grading criteria for CNS WHO Grade 2 meningiomas (brain invasion, mitotic count, cytoarchitectural atypia and histological type) showed a similar risk score distribution as the entire group. Grade 3 meningiomas were allocated to intermediate- (26%) or high-risk groups (74%).Our data suggest that Grade 2 and 3 meningiomas should be prioritised for methylation profiling. A small proportion of Grade 1 meningiomas may also benefit from integrated molecular analysis, and further research is needed to explore if those histologically benign meningiomas with a predicted increased recurrence risk are associated with distinct demographic or histological characteristics.
000301290 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000301290 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301290 650_7 $$2Other$$aCNS WHO grading
000301290 650_7 $$2Other$$ameningioma
000301290 650_7 $$2Other$$amethylation array
000301290 650_7 $$2Other$$amodel score
000301290 650_7 $$2Other$$aprognostication
000301290 650_2 $$2MeSH$$aHumans
000301290 650_2 $$2MeSH$$aMeningioma: genetics
000301290 650_2 $$2MeSH$$aMeningioma: pathology
000301290 650_2 $$2MeSH$$aMeningioma: diagnosis
000301290 650_2 $$2MeSH$$aMeningeal Neoplasms: genetics
000301290 650_2 $$2MeSH$$aMeningeal Neoplasms: pathology
000301290 650_2 $$2MeSH$$aMeningeal Neoplasms: diagnosis
000301290 650_2 $$2MeSH$$aFemale
000301290 650_2 $$2MeSH$$aMale
000301290 650_2 $$2MeSH$$aDNA Methylation
000301290 650_2 $$2MeSH$$aRetrospective Studies
000301290 650_2 $$2MeSH$$aMiddle Aged
000301290 650_2 $$2MeSH$$aAged
000301290 650_2 $$2MeSH$$aAdult
000301290 650_2 $$2MeSH$$aNeoplasm Grading
000301290 650_2 $$2MeSH$$aAged, 80 and over
000301290 7001_ $$aRispoli, Rossella$$b1
000301290 7001_ $$00000-0001-7738-8881$$aJaunmuktane, Zane$$b2
000301290 7001_ $$aMerve, Ashirwad$$b3
000301290 7001_ $$aD'Antona, Linda$$b4
000301290 7001_ $$aDutt, Monika$$b5
000301290 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b6$$udkfz
000301290 7001_ $$00000-0002-9821-0342$$aBrandner, Sebastian$$b7
000301290 773__ $$0PERI:(DE-600)2008293-9$$a10.1111/nan.70018$$gVol. 51, no. 3, p. e70018$$n3$$pe70018$$tNeuropathology & applied neurobiology$$v51$$x0305-1846$$y2025
000301290 909CO $$ooai:inrepo02.dkfz.de:301290$$pVDB
000301290 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000301290 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000301290 9141_ $$y2025
000301290 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-07$$wger
000301290 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROPATH APPL NEURO : 2022$$d2025-01-07
000301290 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000301290 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000301290 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000301290 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000301290 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000301290 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000301290 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000301290 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-07
000301290 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000301290 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000301290 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000301290 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROPATH APPL NEURO : 2022$$d2025-01-07
000301290 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000301290 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000301290 980__ $$ajournal
000301290 980__ $$aVDB
000301290 980__ $$aI:(DE-He78)B300-20160331
000301290 980__ $$aI:(DE-He78)HD01-20160331
000301290 980__ $$aUNRESTRICTED